

# (1R,5S)-6-(4-Methyl-2-oxo-2,5-dihydrofuran-3-yl)-3-phenyl-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-7-one

Dong-Jun Fu <sup>1,2</sup>, Victor Pham <sup>2</sup>, Matthew-Alexander Tippin <sup>2</sup>, Liankun Song <sup>2</sup>, Xiaolin Zi <sup>2</sup>, En Zhang <sup>1</sup> and Hong-Min Liu <sup>1,\*</sup>

<sup>1</sup> School of Pharmaceutical Sciences & Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou University, Zhengzhou 450001, China; zzufdj@sina.com (D.-J.F.); zhangen@zzu.edu.cn (E.Z.)


<sup>2</sup> Department of Urology, University of California, Irvine, Orange, CA 92868, USA; victorp1@uci.edu (V.P.); matthew.tippin@gmail.com (M.-A.T.); liankuns@uci.edu (L.S.); xzi@uci.edu (X.Z.)



\* Correspondence: [liuhm@zzu.edu.cn](mailto:liuhm@zzu.edu.cn); Tel.: +86-371-67781739

*Preparation*

*of*

*(1R,5S)-6-(4-methyl-2-oxo-2,5-dihydrofuran-3-yl)-3-phenyl-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-7-one*





LHM-13FDJ-MS-36

16:34:26

26-Mar-2015

LHM-2198 11 (0.206) AM (Cen,4, 80.00, Ht,5000.0,0.00,1.00); Sm (Mn, 2x3.00); Cm (1:30)

TOF MS ES+  
301

